Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 22, Issue 11, Pages 1541-1559
Publisher
Elsevier BV
Online
2021-10-01
DOI
10.1016/s1470-2045(21)00402-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
- (2021) Felix Y. Feng et al. JAMA Oncology
- Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase 1b Study
- (2020) Edwin M Posadas et al. CLINICAL CANCER RESEARCH
- LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)
- (2020) J.S. de Bono et al. ANNALS OF ONCOLOGY
- Apalutamide and Overall Survival in Prostate Cancer
- (2020) Matthew R. Smith et al. EUROPEAN UROLOGY
- A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.
- (2019) Orazio Caffo et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer
- (2019) Daniel E. Spratt et al. CLINICAL CANCER RESEARCH
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- (2019) Ronald de Wit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
- (2019) Daniel J Khalaf et al. LANCET ONCOLOGY
- Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
- (2018) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer
- (2017) Andrew J. Armstrong et al. EUROPEAN JOURNAL OF CANCER
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy
- (2017) Shuang G. Zhao et al. JAMA Oncology
- A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer
- (2016) Rana R. McKay et al. CLINICAL CANCER RESEARCH
- Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
- (2015) Jack Schalken et al. BJU INTERNATIONAL
- Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer
- (2015) Eleni Efstathiou et al. EUROPEAN UROLOGY
- Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
- (2015) Nicholas David James et al. EUROPEAN UROLOGY
- Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer
- (2015) Matthew R. Smith et al. JOURNAL OF UROLOGY
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Plasma AR and abiraterone-resistant prostate cancer
- (2015) Alessandro Romanel et al. Science Translational Medicine
- Estimating the correlation of bivariate failure times under censoring
- (2013) Michael Schemper et al. STATISTICS IN MEDICINE
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone
- (2011) Eleni Efstathiou et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer
- (2010) M. Yamaoka et al. CLINICAL CANCER RESEARCH
- General Cardiovascular Risk Profile for Use in Primary Care
- (2008) Ralph B. D’Agostino et al. CIRCULATION
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now